Organigram Global Inc

Organigram Global’s shareholders approve full acquisition of Sanity Group and private placement with BAT’s subsidiary, boosting its medical‑marijuana portfolio and growth prospects.

Organigram Global Inc’s stock slides amid high P/E and regulatory threats—learn why investors worry about its future and what it could mean for the cannabis market.

Organigram Global Inc, a leading Canadian medical‑marijuana producer, balances regulatory shifts with strong earnings prospects—investors eye its growth potential amid market turbulence.

Organigram Global Inc. has announced that CEO Beena Goldenberg will retire on September 30, 2025, and a comprehensive CEO selection process has been initiated to identify her successor.

Organigram Global Inc’s recent earnings report and market performance raise concerns about the company’s profitability and long-term sustainability in the competitive medical marijuana industry.